Abstract:AMPK activation appears in a healthy liver during fasting in response to energy generation needs. AMPK enhances FA oxidation and autophagy, reducing lipid accumulation. mTORC1 activation occurs in high food intake in a diseased liver, leading to lipogenesis, reducing FA oxidation, lipolysis, and autophagy, leading to liver lipid accumulation and NAFLD. ACC2, acetyl‐Coa carboxylase 2; AKT, protein kinase B; AMPK, AMP‐activated protein kinase; CPT1, carnitine palmitoyl transferase I; DNL, de novo lipogenesis; FA, fatty acid; GTP, GTPase‐activating protein; HSL, hormone‐sensitive lipase; IR, insulin receptor; LKB, liver kinase B; mTOR, mechanistic target of rapamycin; NAFLD, non‐alcoholic fatty liver disease; PGC‐1α, peroxisome proliferator‐activated receptor‐gamma coactivator‐1 alpha; PI3K, phosphoinositide 3‐ kinase; PPARa, peroxisome proliferator‐activated receptors alpha; RHEB, Ras homolog enriched in the brain; TSC, tuberous sclerosis complex; ULK1, unc‐51‐like kinase 1. Obesity is related to several organs, but the liver is particularly affected. Adenosine monophosphate‐activated protein kinase (AMPK) is a cellular energy sensor and regulator of liver lipid dysfunction and glucose metabolism. The mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. Together, these pathways are involved in obesity, insulin resistance, non‐alcoholic fatty liver disease (NAFLD) and its progression, and autophagy. During energy demand, liver kinase B (LKB) phosphorylation helps activate the AMPK/mTOR pathways. Likewise, the protein forkhead box O family (FOXO) negatively regulates adipogenesis by binding to the promoter sites of peroxisome proliferator‐activated receptor‐gamma coactivator 1‐alpha, initiating adipogenesis. In addition, acetyl‐CoA carboxylase, which regulates de novo lipogenesis, is linked to LKB and FOXO in developing NAFLD. The kinase complex, consisting of Unc‐51‐like autophagy‐activating kinase 1 or 2 (ULK1, ULK2) by stimulating autophagy, and eliminating fat droplets in NAFLD, is regulated by mTORC1 and negatively regulated by AMPK that suppresses liver lipogenesis and increases fatty acid oxidation. Also, ULK1 is essential for initiating phagophore formation, establishing macrophagy, and generating autophagosomes. The selective breakdown of lipid droplets through macroautophagy, or macrolipophagy, occurs on a cellular energy level using free fatty acids. In addition, mTORC1 promotes lipogenesis by activating sterol regulatory element‐binding protein. Finding new components and novel regulatory modes in signaling is significant for a better understanding of the AMPK/mTOR pathways, potentially facilitating the development of future diagnostic and therapeutic strategies for NAFLD and its progression to non‐alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma.

Genetic Liver-Specific AMPK Activation Protects against Diet-Induced Obesity and NAFLD

Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet

The AMPK pathway in fatty liver disease

AMPKα1 Overexpression Alleviates the Hepatocyte Model of Nonalcoholic Fatty Liver Disease Via Inactivating P38mapk Pathway.

Direct β1/β2 AMPK activation reduces liver steatosis but not fibrosis in a mouse model of non-alcoholic steatohepatitis

Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease: Evidence from Studies of Natural Products

AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development

The Role of AMPKα2 in the HFD-induced Nonalcoholic Steatohepatitis.

AMPK/mTOR pathway significance in healthy liver and non‐alcoholic fatty liver disease and its progression

AMPK-activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching

AMPK as a Therapeutic Target for Treating Metabolic Diseases

LB100 Ameliorates Nonalcoholic Fatty Liver Disease Via the AMPK/Sirt1 Pathway.

Myeloid AMPK signaling restricts fibrosis but is not required for metformin improvements during CDAHFD-induced NASH in mice

Activating Adenosine Monophosphate–Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice

A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies

Crosstalk of 5′-Monophosphate-Activated Protein Kinase (AMPK) with Extracellular and Intracellular Signaling Pathways in the Regulation of Nutrient Metabolism and Cell Survival in the Liver

From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases

Novel Small-Molecule AMP-Activated Protein Kinase Allosteric Activator with Beneficial Effects in Db/db Mice

Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function

P7C3-A20 alleviates fatty liver by shaping gut microbiota and inducing FGF21/FGF1, via the AMP-activated protein kinase/CREB regulated transcription coactivator 2 pathway